Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. seeks to expand monkeypox testing as cases rise

Published 06/10/2022, 03:20 PM
Updated 06/10/2022, 03:25 PM
© Reuters. FILE PHOTO: Two samples of suspected cases of monkeypox go through a process of nucleic acid extraction as they get tested at a microbiology lab at La Paz Hospital in Madrid, Spain, June 1, 2022. REUTERS/Susana Vera

By Julie Steenhuysen

CHICAGO (Reuters) - U.S. health officials are working to expand capabilities to test for monkeypox beyond a narrow group of public health labs, heeding calls from infectious disease experts who say testing for the virus needs to become part of routine care.

U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky said during a conference call on Friday that her agency is working with the Food and Drug Administration and Centers for Medicare and Medicaid Services (CMS) to expand testing capacity to include commercial laboratories.

The CDC did not respond to a request for further details.

Currently, preliminary monkeypox testing in the United States is done through a network of 69 public health laboratories, which send results to the CDC for confirmation.

There have been 45 confirmed monkeypox cases in 16 U.S. states so far, with the bulk of the current outbreak outside of Africa, where the virus is endemic, occurring in Europe.

The United States has conducted roughly 300 monkeypox tests. While testing for the virus rose by 45% last week, that needs to increase dramatically if the outbreak is to be contained, infectious disease experts said.

"There is not enough testing going on now for monkeypox in the United States," said Dr. Tom Inglesby, director of the Johns Hopkins Center for Health Security.

"The commercial labs are used to working with healthcare providers from across the country, moving samples around quickly, reporting results quickly in a way that providers understand and expect," he said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Large commercial U.S. testing companies include Quest Diagnostics (NYSE:DGX) and Labcorp.

For commercial labs to do this testing, they need access to monkeypox samples to validate their tests, regulatory guidance from the FDA and commercial billing codes set by CMS, said Inglesby, a former senior White House adviser for the COVID-19 response.

"My sense is all of that is moving forward," he said.

In a detailed report of 17 cases published by the CDC last week, most patients identified as men who have sex with men.

In many of the cases, the monkeypox rash started in the genital area, which could lead some doctors to misdiagnose it as a more common sexually transmitted infection such as herpes or syphilis.

"Monkeypox symptoms are mimicking other sexually transmitted infections," said David Harvey, executive director of the National Coalition of Sexually Transmitted Disease Directors. "We need to mount a bigger national response."

The Association of Public Health Laboratories said it has plenty of capacity now, but would work to expand testing to commercial labs should the outbreak continue to grow.

Latest comments

Flagrant and predictable as ever, the curtain rises on the "late trade" magic show, as the BIGGEST INVESTMENT JOKE IN THE WORLD "rallies" into the close on FRAUDULENT Friday.  Assume the proper position for the weekend America.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.